Skip to content
thestock.space

On 6 Nov 2026, Dr. Lal Path Labs was priced at ₹1,970.00, or 56.5× trailing earnings, against an industry P/E of 52.8×. Sales and net profit grew 11% and 28% a year over 3 years; its ROCE of 26% is the second-highest among the 7 largest Diagnostics & Research peers. It carries very little debt, and its dividend yield is 1.0%. It is a small-cap company with a market cap of ₹32,941 Cr, ranked 2nd of 18 Diagnostics & Research companies by market cap; the shares rose 25% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,962.00
Day high
₹2,011.00
Day low
₹1,935.00
Prev. close
₹1,966.80
Volume
5.7 L

Health check

3 good · 3 fair
  • ReturnsAhead

    +24.7% over a year, better than 5 of 7 peers.

  • Price tagIn line

    P/E 56.5 vs industry 52.8.

  • GrowthSteady

    Sales +11.1%, profit +28.3% a year over 3 years.

  • ProfitabilityStrong

    ROCE 25.7% vs peer median 18.1%.

  • Balance sheetFair

    Debt 0.08× equity, interest covered 30.3×, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹32,941 Cr, #2 of 18 in its industry by size.

Defensive

Beta 0.20 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹3,034 Cr · profit ₹583 Cr
Market cap
₹32,941 Cr
Small cap
P/E
56.5
Industry 52.8
Price to book
11.99
Peers 7.17
Dividend yield
1.02%
ROE
22.6%
Peers 15.1%
ROCE
25.7%
Peers 18.1%
Debt to equity
0.08
Debt ₹233 Cr
EPS (TTM)
₹34.87
Face value ₹10
OPM (TTM)
30.2%
Net margin 19.2%
Sales growth
+19.6%
Latest quarter vs a year ago
Profit growth
+27.4%
Latest quarter vs a year ago
Price to sales
10.86
EV/EBITDA 37.0

Strengths and risks

Strengths

  • Return on equity of 22.6%.
  • Return on capital employed of 25.7%.
  • Practically debt-free.
  • Quarterly profit up 27.4% on a year ago.
  • Quarterly sales up 19.6% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Dr. Lal Path Labs

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is…

Headquarters
Gurugram
Employees
5,206
Sector
Healthcare
ISIN
INE600L01024
Website
lalpathlabs.com

Price range

52 weeks

₹1,272.60₹2,061.90

Today

₹1,935.00₹2,011.00
Avg volume (3M)
2.8 L
1-year return
plus 24.7%
From 52-week high
minus 4.5%

Analyst consensus

26 analysts
BuyMean target ₹2,069.15 plus 5.0%

Target range, with today’s price

Low ₹1,180.00High ₹2,500.00

Next results expected around 5 Feb 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Diagnostics & Research

Compare with peersScreen the whole industry
Company
SAILIFESai Life Sciences1,785.10plus 11.95%37,929101.515.2218.1%15.1%28.7%21.3%226.8%0.00%plus 72.7%
LALPATHLABDr. Lal Path Labs1,970.00plus 0.16%32,94156.511.9925.7%22.6%30.2%11.1%28.3%1.02%plus 24.7%
SYNGENESyngene International417.30plus 0.77%16,77290.33.468.3%3.9%25.7%5.4%−12.0%0.30%minus 36.0%
VIJAYAVijaya Diagnostic Centre1,468.60plus 2.15%15,12674.414.2919.1%21.2%43.1%21.0%26.9%0.14%plus 40.2%
METROPOLISMetropolis Healthcare568.75minus 0.39%11,80352.87.1715.7%14.6%21.7%12.7%10.0%0.35%plus 12.5%
THYROCAREThyrocare Technologies493.10plus 0.68%7,84855.014.7533.8%26.4%32.2%16.7%36.2%1.89%plus 8.3%
VIMTALABSVimta Labs496.45minus 2.14%2,21927.94.5221.0%17.7%34.7%8.9%17.2%0.40%minus 23.3%
SURAKSHASuraksha Diagnostic333.55plus 0.68%1,73748.57.0714.7%14.1%21.8%17.7%70.3%0.15%plus 2.2%
Median of 7 peers–0.68%11,80355.07.1718.1%15.1%28.7%16.7%26.9%0.30%8.3%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26Sep 26
670–660703798874
478–481492550594
192–179211248280
28.7%–27.2%30.0%31.0%32.1%
28.1–24.4031.934.2
4.7–7.26.16.37
34.6–42.144.644.446.9
––−30.1–––
181–124160229261
26.0%–26.5%17.4%25.4%25.6%
132–90.5131170192
–9.015.417.8510.1311.47

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+11.1%
Profit CAGR 3Y
+28.3%
EPS CAGR 3Y
+28.1%
ROE
22.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,0172,2272,4612,763
–+10.4%+10.5%+12.3%
1,5231,6161,6721,909
494610789854
24.5%27.4%32.1%30.9%
33.257.5−183.1
37.529.422.322.8
150144142162
4.310.418−3.1
344505625669
29.9%28.3%21.2%23.8%
239358487505
–+49.8%+36.2%+3.6%
14.3721.4929.2030.20

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
83.483.583.6168
1,5831,7662,0892,341
419247157199
300360387439
2,3862,4562,7173,146
405348343490
3.95.46.95.9
26.419.367.7196
8149431,1641,331
1,1361,1401,1361,124
2,3862,4562,7173,146

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
456535569636
−287−24.3−303−422
−283−414−334−264
−11497.2−68.3−49.8
−44.6−57.4−53.9−173
411478515462
−103−201−207−223

Shareholding pattern

Source: NSE filings
52.9%
promoters
  • Promoters52.93%
  • Public46.66%
  • Employee trusts0.41%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202652.93%46.66%minus 0.26
30 Jun 202653.19%46.43%minus 0.02
31 Mar 202653.21%46.44%0.00
31 Dec 202553.21%46.44%0.00
22 Dec 202553.21%46.44%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you